The Global Ophthalmic Packaging Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights – outlining the key outcomes of the Ophthalmic Packaging market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/ophthalmic-packaging-market-13964

Recent Development

  • Aptar Pharma: preservative-free Ophthalmic Squeeze Dispenser (OSD) launched with Bausch + Lomb’s Levofree Multidose in France; also launched with Santen’s Taflotan/Saflutan in Europe.

  • Berry Global: new easy-squeeze 10 ml ophthalmic bottle qualified for use with Aptar’s OSD.

  • Nemera: ongoing scale-up of Novelia® (multidose, preservative-free eye-dropper system) with updated technical literature (Mar 2024).

  • TekniPlex Healthcare: announced expanded EU capacity for injection-blow-molded bottles and multilayer films (Pharmapack/Pack Expo cycle).

  • Gerresheimer: strategic refocus on pharma/biotech; plan to separate Moulded Glass unit (Aug 5 2025).

  • SCHOTT Pharma: launched syringe & cartridge glass tubing in India (Aug 8 2025), strengthening primary pharma packaging supply in APAC.

Drivers

  • Growing prevalence of ocular diseases (dry eye, glaucoma) and Rx/OTC eye-drops; shift to multidose, preservative-free delivery.

  • Brand owner demand for patient-centric devices (ease-of-squeeze, one-drop dosing) and compliance.

Restraints

  • Sterility/contamination risk in multidose formats drives stringent validation and cost.

  • Material and regulatory constraints (extractables/leachables, preservative restrictions) limit design freedom.

Regional segmentation analysis

  • Global market estimated ~US$1.82 B (2024) with ~5.4% CAGR to 2034 (FMI); alternative estimates put US$7.35 B (2024) to US$15.89 B by 2032/34 (methodology varies). APAC capacity additions (India) are notable.

Emerging Trends

  • Preservative-free multidose systems (filter membranes/antimicrobial tips) becoming standard.

  • Easy-squeeze bottles and ergonomic formats to improve dosing accuracy.

  • Sustainable materials (recyclable/PCr-content films & bottles) and regionalization of primary glass supply.

Top Use Cases

  • Eye-drop systems (multidose preservative-free droppers, monodose vials),

  • Primary glass (vials, cartridges) for ophthalmic injectables (e.g., anti-VEGF),

  • Secondary/tertiary packs for sterile handling & cold chain.

Major Challenges

  • Achieving microbiological integrity without preservatives; controlling drop size/accuracy for home users.

  • Supply-chain complexity (components from multiple vendors) and validation timelines.

Attractive Opportunities

  • Co-developed device + bottle platforms (Aptar OSD + Berry bottle) for rapid market entry.

  • APAC manufacturing for glass/cartridges to derisk supply and cost.

  • Value-added coatings/films and IBR/IBR-ML (multi-layer) bottles for barrier & shelf-life gains.

Key factors of market expansion

  • Device innovations that enable preservative-free multidose adoption (Aptar OSD, Nemera Novelia).

  • Easier-to-use primary containers (ergonomic, low-force squeeze) to support adherence.

  • Strategic portfolio moves concentrating on pharma packaging core (Gerresheimer; SCHOTT Pharma India launch).

“Company with values” — who does what (reference list)

  • Aptar Pharma — market-leading OSD (preservative-free multidose) adopted by Bausch + Lomb and Santen.

  • Nemera — Novelia® platform (one-drop, contamination control) for multidose eye drops.

  • Berry Global — 10 ml ophthalmic bottle qualified for Aptar OSD; focus on ease-of-squeeze.

  • Gerresheimer — broad pharma packaging/devices; moulded-glass separation to sharpen pharma focus.

  • SCHOTT Pharma — primary glass leader; new syringe/cartridge tubing capacity in India (relevant to ophthalmic injectables).

  • TekniPlex Healthcare — bottles/films; expanding EU capacity and sustainable films.

  • West Pharmaceutical Services — components & containment; actively developing ophthalmic solutions and posting strong growth in proprietary products (context).

  • SGD Pharma — glass dropper bottles (5–100 ml) for ophthalmic/diagnostic uses.

Market size context

  • FMI: US$1.82 B (2024) → US$3.06 B (2034), 5.4% CAGR. Alternative estimate: US$7.35 B (2024) → US$15.89 B (2032) (different scope/methodology). Choose one model and cite consistently in your deck.

If you want, I can turn this into a one-page slide with a player map (device vs. primary glass) and a mini timeline of 2024–2025 launches.

4K-Smart-OLED-TV.jpg